Pharmaceutical company Novartis, operating in 155 countries around the world, announced plans to merge with American Endocyte, the developer of targeted therapies for cancer treatment, finversia.ru writes. Novartis, according to the agreement, will pay $2 billion 100 million for an American company, acquiring all its ordinary shares at $24 per share, which is 1.5 times more than the price of one share at 5 dollars 56 cents at the closure of trading on Wednesday. The deal must also be approved by Endocyte shareholders and regulators.
Korean Air plans to sell new shares worth $817 Million to stay afloat13.05.2020
Bloomberg: Nissan restructuring plan includes $2.8 billion-cut12.05.2020
Richard Branson to sell $25 Million worth of Virgin Galactic shares amid virus outbreak07.05.2020
Liberty and Telefonica agrees for a $38 billion deal to take on BT